JP4916889B2 - 血管新生を調節するための方法および組成物 - Google Patents

血管新生を調節するための方法および組成物 Download PDF

Info

Publication number
JP4916889B2
JP4916889B2 JP2006552252A JP2006552252A JP4916889B2 JP 4916889 B2 JP4916889 B2 JP 4916889B2 JP 2006552252 A JP2006552252 A JP 2006552252A JP 2006552252 A JP2006552252 A JP 2006552252A JP 4916889 B2 JP4916889 B2 JP 4916889B2
Authority
JP
Japan
Prior art keywords
ccx
ckr2
cells
mmol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006552252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520564A (ja
JP2007520564A5 (enExample
Inventor
ジェニファー バーンズ
ブレットン サマーズ
ユー ワン
モーリーン ハワード
トーマス シャル
チェンホア ミャオ
Original Assignee
ケモセントリックス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス インコーポレーティッド filed Critical ケモセントリックス インコーポレーティッド
Publication of JP2007520564A publication Critical patent/JP2007520564A/ja
Publication of JP2007520564A5 publication Critical patent/JP2007520564A5/ja
Application granted granted Critical
Publication of JP4916889B2 publication Critical patent/JP4916889B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006552252A 2004-02-03 2005-02-02 血管新生を調節するための方法および組成物 Expired - Fee Related JP4916889B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54184904P 2004-02-03 2004-02-03
US60/541,849 2004-02-03
US59895804P 2004-08-04 2004-08-04
US60/598,958 2004-08-04
US62619504P 2004-11-08 2004-11-08
US60/626,195 2004-11-08
PCT/US2005/003521 WO2005074645A2 (en) 2004-02-03 2005-02-02 Methods and compositions for modulating angiogenesis

Publications (3)

Publication Number Publication Date
JP2007520564A JP2007520564A (ja) 2007-07-26
JP2007520564A5 JP2007520564A5 (enExample) 2008-03-27
JP4916889B2 true JP4916889B2 (ja) 2012-04-18

Family

ID=34841735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552252A Expired - Fee Related JP4916889B2 (ja) 2004-02-03 2005-02-02 血管新生を調節するための方法および組成物

Country Status (7)

Country Link
US (1) US20050214287A1 (enExample)
EP (1) EP1715892A4 (enExample)
JP (1) JP4916889B2 (enExample)
AU (1) AU2005209921B2 (enExample)
CA (1) CA2554880A1 (enExample)
IL (1) IL177104A (enExample)
WO (1) WO2005074645A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417062B2 (en) 2004-09-29 2008-08-26 Chemocentryx, Inc. Substituted arylamides
EP1909575A2 (en) * 2005-06-29 2008-04-16 ChemoCentryx Inc Substituted n-cinnamyl benzamides
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
DK2349273T3 (en) * 2008-11-04 2015-07-13 Chemocentryx Inc Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
KR102196374B1 (ko) 2012-11-29 2020-12-31 케모센트릭스, 인크. Cxcr7 길항제
BR112021011222A2 (pt) 2018-12-12 2021-08-24 Chemocentryx, Inc. Inibidores de cxcr7 para o tratamento de câncer
CN111593022B (zh) * 2018-12-27 2023-10-24 广州溯原生物科技股份有限公司 vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用
EP4326257A4 (en) 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515854A (ja) * 2002-12-20 2006-06-08 ケモセントリックス， インコーポレイテッド ヒト腫瘍発現ｃｃｘｃｋｒ２の阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020166133A1 (en) * 1998-02-10 2002-11-07 Millennium Pharmaceuticals, Inc Neokine protein and nucleic acid molecules and uses therefor
EP1061944B1 (en) * 1998-03-13 2004-01-28 The University Of British Columbia Therapeutic chemokine receptor antagonists
US20020107196A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
WO2002022599A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
JPWO2002094261A1 (ja) * 2001-05-24 2004-09-02 呉羽化学工業株式会社 含窒素化合物からなるｃｘｃｒ４拮抗作用を有する薬剤
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20060275769A1 (en) * 2003-01-06 2006-12-07 Oregon Health & Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515854A (ja) * 2002-12-20 2006-06-08 ケモセントリックス， インコーポレイテッド ヒト腫瘍発現ｃｃｘｃｋｒ２の阻害剤

Also Published As

Publication number Publication date
JP2007520564A (ja) 2007-07-26
EP1715892A2 (en) 2006-11-02
WO2005074645A2 (en) 2005-08-18
IL177104A0 (en) 2006-12-10
AU2005209921B2 (en) 2011-04-07
AU2005209921A1 (en) 2005-08-18
WO2005074645A3 (en) 2005-12-22
IL177104A (en) 2010-12-30
EP1715892A4 (en) 2008-07-09
CA2554880A1 (en) 2005-08-18
US20050214287A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
Dinarello The IL-1 family of cytokines and receptors in rheumatic diseases
Han et al. Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis
Struyf et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4
JP4916889B2 (ja) 血管新生を調節するための方法および組成物
JP4755107B2 (ja) ケモカイン受容体に関連する疾患および状態を検出および処置するための組成物および方法
CN110194787B (zh) 靶向抑制Wnt/β-catenin信号活性的多肽及其用途
KR20060136373A (ko) 케모카인 수용체와 관련된 질병 및 증상의 검출 및 치료용조성물 및 방법
Jiang et al. Development of small-molecules targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)—Receptor Activator of Nuclear Factor-κB (RANK) protein–protein interaction by structure-based virtual screening and hit optimization
Tacconi et al. Antibody-mediated delivery of VEGFC ameliorates experimental chronic colitis
Rafei et al. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis
IL175179A (en) A method of scanning for a factor that links ccx – ckr2 on a cell, and its use to detect the presence or absence of cancer
CN107438433B (zh) 含2-甲氧基-4-(3-(4-甲氧基苯基)丙-1-烯-1-基)苯酚作为活性成分的防治关节炎或炎性疾病的药物组合物
KR101149115B1 (ko) 혈관신생을 조절하기 위한 방법 및 조성물
US20240117023A1 (en) Method
US20100247540A1 (en) Methods and Compositions For Modulating Angiogenesis
MXPA06008680A (es) Metodos y composiciones para modular la angiogenesis
US20230322805A1 (en) Novel pyrimidodiazepine derivatives or uses thereof
JP7759032B2 (ja) 脳血管攣縮抑制剤
Dell'Accio et al. Molecular response to cartilage injury
Remans et al. Free radicals regulate glucocorticoid-induced apoptosis in T lymphocytes
Fearon et al. Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
Stummvoll et al. Autoreactive T cells to histone H1 and core histones in patients with systemic lupus erythematosus
Palmer et al. Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120123

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120125

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4916889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees